What it's for (Indications)
- Betamethasone dipropionate, topical, in combination with salicylic acid, is indicated for the short-term treatment of inflammatory and pruritic manifestations of hyperkeratotic and corticosteroid-responsive dermatoses.
- This includes conditions such as psoriasis (particularly chronic plaque psoriasis), severe atopic dermatitis, chronic eczema, and other eczematous conditions where significant scaling, thickening (lichenification), or dryness of the skin is a prominent feature.
- The inclusion of salicylic acid serves to facilitate the desquamation of hyperkeratotic layers, thereby enhancing the penetration of the potent corticosteroid betamethasone dipropionate into the affected epidermal and dermal layers.
- This dual action helps to reduce inflammation, alleviate pruritus, and diminish the characteristic scaling and thickening of these dermatological conditions.
- It is specifically designed for situations where the keratolytic effect is necessary to augment corticosteroid efficacy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | A thin film of betamethasone dipropionate and salicylic acid topical formulation should be applied to the affected skin areas once or twice daily, as directed by a healthcare professional. The precise frequency and duration of treatment must be individualized based on the severity of the condition, the patient's response, and the potential for adverse effects. Treatment should generally be limited to a maximum of two weeks in adults and even shorter periods in pediatric patients, typically no more than one week. The total amount applied should not exceed 50 grams per week for adults to minimize the risk of systemic absorption. Application should be confined strictly to the affected areas, avoiding the face, groin, axillae, and large body surfaces. Occlusive dressings should not be used unless specifically prescribed by a physician due to the increased risk of systemic absorption and local adverse reactions. Patients should be instructed to wash their hands thoroughly before and after application. |
Safety & Warnings
Common Side Effects
- Common local adverse reactions associated with the use of betamethasone dipropionate and salicylic acid include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
- Systemic adverse effects, though less common with topical administration, can occur due to absorption of both active components.
- Betamethasone dipropionate, being a potent corticosteroid, can lead to hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria, particularly with prolonged use, application to large surface areas, occlusive dressings, or in pediatric patients.
- Salicylic acid, when absorbed systemically, can cause salicylism, characterized by symptoms such as tinnitus, nausea, vomiting, dizziness, hyperpnea, and mental confusion, especially in children, patients with impaired renal function, or with extensive application to broken skin.
- Ocular side effects like cataracts and glaucoma have been reported with prolonged topical corticosteroid use, particularly near the eyes.
Serious Warnings
- Black Box Warning: While a formal FDA-mandated black box warning has not been issued for topical betamethasone dipropionate and salicylic acid combination products, healthcare professionals and patients must be acutely aware of significant potential risks, particularly concerning systemic absorption of both active components. Potent topical corticosteroids like betamethasone dipropionate can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria, especially with prolonged use, application to large surface areas, occlusive dressings, or in pediatric patients. Children are particularly susceptible to systemic toxicity due to a higher skin surface area-to-body mass ratio and immature skin barrier function, which increases corticosteroid absorption and subsequent HPA axis suppression and growth retardation. Salicylic acid, especially when applied extensively, to broken skin, or under occlusion, can lead to systemic salicylate toxicity (salicylism), characterized by symptoms such as tinnitus, nausea, vomiting, dizziness, and hyperpnea, which can be life-threatening. Therefore, this medication should be used with extreme caution, strictly for the shortest duration possible, on the smallest affected area, and without occlusion unless explicitly directed by a physician. Avoid use in infants and young children, and on the face, groin, or axillae. Prompt discontinuation is warranted if signs of systemic adverse effects or significant local irritation occur. Regular monitoring for HPA axis suppression and salicylate toxicity is advisable, particularly in at-risk populations and during prolonged treatment periods.
- Systemic absorption of both betamethasone dipropionate and salicylic acid can occur, leading to potential systemic adverse effects.
- Potent topical corticosteroids can cause reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.
- This risk is amplified in children, with prolonged use, large surface area application, or under occlusive dressings.
- Children are particularly susceptible to systemic toxicity due to a higher surface area-to-body mass ratio.
- Salicylic acid absorption, especially when applied extensively or to broken skin, may result in salicylism.
- Therefore, caution is paramount in pediatric patients and those with renal impairment.
- This medication should not be used on the face, groin, or axillae, or in the diaper area under occlusive dressings, due to increased risk of local and systemic side effects.
- Avoid contact with the eyes and mucous membranes.
- Discontinue use if irritation, sensitization, or excessive dryness develops.
- If skin infection is present, appropriate antimicrobial therapy should be co-administered; if infection is not controlled, discontinue the corticosteroid.
- Prolonged use should be avoided, as it increases the risk of both local skin atrophy and systemic adverse effects.
- Pregnancy and lactation require careful consideration of benefits versus risks.
How it Works (Mechanism of Action)
The therapeutic effects of this combination product are derived from the distinct pharmacological actions of its two active components. Betamethasone dipropionate is a potent (Group I) synthetic corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene expression. This leads to the inhibition of phospholipase A2, thereby preventing the release of arachidonic acid and the subsequent synthesis of inflammatory mediators like prostaglandins and leukotrienes. Additionally, it suppresses the immune response by inhibiting the migration of inflammatory cells and reducing the proliferation of lymphocytes, ultimately decreasing erythema, edema, and itching. Salicylic acid acts as a keratolytic agent by dissolving the intercellular cement in the stratum corneum, promoting the desquamation of epidermal cells. This action helps to remove scales and reduce hyperkeratosis, thereby allowing the potent betamethasone dipropionate to penetrate more effectively through the thickened skin barrier. The combined action provides synergistic relief from inflammatory dermatoses characterized by excessive scaling and thickening.
Commercial Brands (Alternatives)
No other brands found for this formula.